Spectrum pays Bayer €19 million for ex-US Zevalin rights
This article was originally published in Scrip
Executive Summary
In a deal worth €19 million ($24.9 million), Spectrum Pharmaceuticals is to acquire from Bayer Healthcare the licensing rights to market the non-Hodgkin's lymphoma treatment, Zevalin (ibritumomab tiuxetan) injection for intravenous use outside the US.